Abstract Number: 124 • 2019 ACR/ARP Annual Meeting
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Background/Purpose: Circulating CD4 T cells that express CXCR5 together with PD-1 and/or ICOS are considered as counterparts of bona fide Tfh cells and function as…Abstract Number: 208 • 2019 ACR/ARP Annual Meeting
Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
Background/Purpose: Sleep disturbances (SD) are reported to be common in RA but relatively few studies have addressed the issue. We examined the frequency and severity…Abstract Number: 414 • 2019 ACR/ARP Annual Meeting
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Background/Purpose: With the advent of biologic therapy for RA, the American College of Rheumatology advocates a treat to target (TTT) approach in the treatment of…Abstract Number: 457 • 2019 ACR/ARP Annual Meeting
Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
Background/Purpose: Altered body composition is a common feature of patients with rheumatoid arthritis (RA), up to two-thirds of affected patients showing loss of muscle mass…Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…Abstract Number: 540 • 2019 ACR/ARP Annual Meeting
Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
Background/Purpose: In Germany, the first etanercept biosimilar was licensed in 2016. In contrast to other European countries there is no uniform recommendation for the prescription…Abstract Number: 843 • 2019 ACR/ARP Annual Meeting
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Background/Purpose: Risk factors for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a significant cause of morbidity and mortality, are poorly understood. RA-ILD detection is limited by…Abstract Number: 974 • 2019 ACR/ARP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Background/Purpose: Clinical development of BTK/Tec family kinase inhibitors for treating autoimmune diseases has lagged that of their successful application in oncology. The lack of selective…Abstract Number: 1177 • 2019 ACR/ARP Annual Meeting
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Background/Purpose: Near infrared (NIR) imaging of indocyanine green (ICG) in rheumatoid arthritis (RA) models identified abnormal lymphatic vessel (LV) function, which can be quantified as…Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…Abstract Number: 1372 • 2019 ACR/ARP Annual Meeting
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Background/Purpose: The adherence to the therapeutic regimen in patients with Rheumatoid Arthritis (RA) varies between 30 and 80%. Classically, it is mentioned that the adherence…Abstract Number: 1408 • 2019 ACR/ARP Annual Meeting
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Background/Purpose: Via a systematic literature review of contemporary efficacy data of pharmacological therapies in RA we sought to inform the 2019 update of the EULAR…Abstract Number: 1440 • 2019 ACR/ARP Annual Meeting
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Background/Purpose: Therapeutic drug monitoring (TDM) would be important if there was evidence to support the utility of measured drug concentrations in making changes to dose…Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…Abstract Number: 2005 • 2019 ACR/ARP Annual Meeting
Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune inflammatory disease causing erosive and disabling joint damage. We recently found that mitochondria are extruded upon formation of…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 56
- Next Page »